Cardiol Therapeutics Inc. (CRDL) Form 6-K — Nov 3, 2026
Cardiol Therapeutics (NASDAQ: CRDL) has entered into an at-the-market equity offering agreement with Jefferies LLC allowing it to sell up to US$75 million of common shares from time to time at prevailing market prices on Nasdaq. Proceeds are earmarked for developing CardiolRx for recurrent pericarditis — including a potential New Drug Application depending on Phase III MAVERIC trial outcomes — plus CRD-38 clinical development and general corporate purposes.
Key figures
- Gross Proceeds
- 75000000
- Currency
- USD
- Offering type
- at-the-market (ATM) equity program
- Base prospectus date
- 2026-09-15
- Registration statement
- Form F-10 File No. 333-298852
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.